ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 313,56
-0,57%
Dow Jones
42 732,78
-0,60%
DAX
19 909,14
-0,25%
Brent Oil
74,095
0,64%
Bitcoin
94 645,34
1,21%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Cardiff Oncology Inc (CRDF) Cours

Cardiff Oncology Inc

Cardiff Oncology Inc (CRDF)

NASDAQ
4,25
-0,07
( -1,62% )
Mis à jour : 20:59:14
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
4,25
Prix Achat
4,25
Prix Vente
4,26
Volume échangé
659 230
4,14 Fourchette du Jour 4,5208
1,44 Plage de 52 semaines 6,42
Cap du marché
217,318M
Clôture Veille
4,32
Ouverture
4,30
Dernière Transaction
2
@
4.255
Dernière heure de transaction
21:00:04
Volume financier
US$ 2 806 794
VWAP
4,2577
Volume moyen (3 m)
2 050 249
Actions en circulation
51 133 747
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,47
Bénéfice par action (BPA)
-0,81
Chiffre d'affairess
488k
Bénéfice net
-41,47M

À propos de Cardiff Oncology Inc

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias. Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
cardiffoncology.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Cardiff Oncology Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker CRDF. Le dernier cours de clôture d'Cardiff Oncology était de US$4,32. Au cours de la dernière année, les actions de Cardiff Oncology ont été négociées dans une fourchette de prix de US$ 1,44 à US$ 6,42.

Cardiff Oncology compte actuellement 51 133 747 actions en circulation. La capitalisation boursière d'Cardiff Oncology est de US$220,90 million. Cardiff Oncology a un ratio cours/bénéfice (ratio PE) de -1.47.

CRDF Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

18 Décembre 2024
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

17 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

16 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

10 Décembre 2024
Edgar (US Regulatory)

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to...

10 Décembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

10 Décembre 2024
Edgar (US Regulatory)

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the...

10 Décembre 2024
GlobeNewswire Inc.

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc...

19 Novembre 2024
GlobeNewswire Inc.

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data...

07 Novembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.14-3.189066059234.394.543.8210933364.15749988CS
41.6362.2137404582.625.63952.2645771373.88910495CS
121.660.37735849062.655.63952.2620502493.64830596CS
262.0492.30769230772.215.63952.0112069943.38268254CS
522.77187.1621621621.486.421.4411923973.53406781CS
156-1.62-27.5979557075.877.320.947709452.87527819CS
2602.96229.4573643411.2925.50.7019038605.83930997CS

CRDF - Frequently Asked Questions (FAQ)

What is the current Cardiff Oncology share price?
The current share price of Cardiff Oncology is US$ 4,25
How many Cardiff Oncology shares are in issue?
Cardiff Oncology has 51 133 747 shares in issue
What is the market cap of Cardiff Oncology?
The market capitalisation of Cardiff Oncology is USD 220,9M
What is the 1 year trading range for Cardiff Oncology share price?
Cardiff Oncology has traded in the range of US$ 1,44 to US$ 6,42 during the past year
What is the PE ratio of Cardiff Oncology?
The price to earnings ratio of Cardiff Oncology is -1,47
What is the cash to sales ratio of Cardiff Oncology?
The cash to sales ratio of Cardiff Oncology is 125,26
What is the reporting currency for Cardiff Oncology?
Cardiff Oncology reports financial results in USD
What is the latest annual turnover for Cardiff Oncology?
The latest annual turnover of Cardiff Oncology is USD 488k
What is the latest annual profit for Cardiff Oncology?
The latest annual profit of Cardiff Oncology is USD -41,47M
What is the registered address of Cardiff Oncology?
The registered address for Cardiff Oncology is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Cardiff Oncology website address?
The website address for Cardiff Oncology is cardiffoncology.com
Which industry sector does Cardiff Oncology operate in?
Cardiff Oncology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NXUNXU Inc
US$ 1,50
(516,27%)
546,18M
WATTEnergous Corporation
US$ 1,53
(272,08%)
180,78M
HOLOMicroCloud Hologram Inc
US$ 6,97
(190,42%)
186,96M
INTZIntrusion Inc
US$ 5,0996
(136,09%)
126,85M
SMXSMX Security Matters Public Company
US$ 0,7169
(102,74%)
328,34M
ABPAbpro Holdings Inc
US$ 2,075
(-53,79%)
1,86M
LITMSnow Lake Resources Ltd
US$ 0,9802
(-38,74%)
57,12M
TRAWTraws Pharma Inc
US$ 8,60
(-35,92%)
1,06M
LNKSLinkers Industries Ltd
US$ 1,94
(-28,94%)
755,2k
MYSZMy Size Inc
US$ 4,9457
(-24,03%)
1,27M
NXUNXU Inc
US$ 1,495
(514,22%)
546,24M
SMXSMX Security Matters Public Company
US$ 0,7169
(102,74%)
328,34M
VINCVincerx Inc
US$ 0,327
(68,56%)
325,09M
XTIAXTI Aerospace Inc
US$ 0,03995
(1,14%)
231,76M
HOLOMicroCloud Hologram Inc
US$ 6,99
(191,25%)
186,97M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CRDF
Cardiff Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés